{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T19:15:58Z","timestamp":1790709358871,"version":"4.1.0"},"reference-count":68,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,8,4]],"date-time":"2025-08-04T00:00:00Z","timestamp":1754265600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,8,4]],"date-time":"2025-08-04T00:00:00Z","timestamp":1754265600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Attralus, Inc.","award":["Collaborative Research Award"],"award-info":[{"award-number":["Collaborative Research Award"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["npj Drug Discov."],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>In systemic amyloidosis, the progressive accumulation of amyloid fibrils along with extracellular matrix components causes organ dysfunction, reduced quality of life, and is often fatal. Currently, twenty different proteins have been identified in systemic amyloid fibrils. Therapeutic elimination of tissue amyloid may improve organ function and patient outcomes. Amyloid-reactive immunoglobulins capable of stimulating cell-mediated clearance of amyloid deposits represent promising therapeutic strategies. AT-02 (zamubafusp alfa) is an immunoglobulin-peptide fusion protein comprising a humanized IgG1 and a pan-amyloid reactive peptide, p5R. AT-02 binds two ubiquitous components of all amyloids, namely amyloid fibrils and highly sulfated heparan sulfate glycans. This fusion protein exhibits specific reactivity with many amyloid types, obviating the need for individualized immunoglobulins for therapy. We demonstrate that AT-02 is an effective opsonin for amyloid by enhancing phagocytosis of amyloid extracts and inducing complement fixation. These data suggest that pan-amyloid binding reagents may provide novel treatment options for amyloid removal.<\/jats:p>","DOI":"10.1038\/s44386-025-00015-4","type":"journal-article","created":{"date-parts":[[2025,8,4]],"date-time":"2025-08-04T06:27:50Z","timestamp":1754288870000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["The antibody-peptide fusion protein, AT-02, is an effective opsonin with pan-amyloid reactivity"],"prefix":"10.1038","volume":"2","author":[{"given":"J. S.","family":"Wall","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A. D.","family":"Williams","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Balachandran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T. J.","family":"Hancock","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Richey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A. C.","family":"Stuckey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Macy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Wooliver","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E. B.","family":"Martin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. W.","family":"Jackson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R. E.","family":"Heidel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Guthrie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. L.","family":"Klein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Angell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S. J.","family":"Kennel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. S.","family":"Foster","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,8,4]]},"reference":[{"key":"15_CR1","doi-asserted-by":"publisher","first-page":"778","DOI":"10.1001\/jama.2024.0442","volume":"331","author":"FL Ruberg","year":"2024","unstructured":"Ruberg, F. L. & Maurer, M. S. Cardiac amyloidosis due to transthyretin protein: a review. JAMA 331, 778\u2013791 (2024).","journal-title":"JAMA"},{"key":"15_CR2","doi-asserted-by":"publisher","first-page":"101040","DOI":"10.1016\/j.blre.2023.101040","volume":"59","author":"A Sabinot","year":"2023","unstructured":"Sabinot, A. et al. State-of-the-art review on AL amyloidosis in Western Countries: Epidemiology, health economics, risk assessment and therapeutic management of a rare disease. Blood Rev. 59, 101040 (2023).","journal-title":"Blood Rev."},{"key":"15_CR3","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-022-02414-6","volume":"17","author":"N Kumar","year":"2022","unstructured":"Kumar, N. et al. Global epidemiology of amyloid light-chain amyloidosis. Orphanet J. Rare Dis. 17, 278 (2022).","journal-title":"Orphanet J. Rare Dis."},{"key":"15_CR4","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1111\/joim.13169","volume":"289","author":"E Muchtar","year":"2021","unstructured":"Muchtar, E. et al. Systemic amyloidosis from A (AA) to T (ATTR): a review. J. Intern. Med 289, 268\u2013292 (2021).","journal-title":"J. Intern. Med"},{"key":"15_CR5","doi-asserted-by":"publisher","first-page":"1344","DOI":"10.1093\/ehjci\/jew325","volume":"18","author":"DF Hutt","year":"2017","unstructured":"Hutt, D. F. et al. Prognostic utility of the Perugini grading of 99mTc-DPD scintigraphy in transthyretin (ATTR) amyloidosis and its relationship with skeletal muscle and soft tissue amyloid. Eur. Heart J. Cardiovasc. Imaging 18, 1344\u20131350 (2017).","journal-title":"Eur. Heart J. Cardiovasc. Imaging"},{"key":"15_CR6","first-page":"217","volume":"41","author":"A Waheed","year":"2023","unstructured":"Waheed, A. & Dorbala, S. Current status of Radionuclide imaging of transthyretin cardiac amyloidosis. Cardiol. Clin. 41, 217\u2013231 (2023).","journal-title":"Cardiol. Clin."},{"key":"15_CR7","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1001\/jama.2020.5493","volume":"324","author":"MA Gertz","year":"2020","unstructured":"Gertz, M. A. & Dispenzieri, A. Systemic Amyloidosis recognition, prognosis, and therapy: a systematic review. JAMA 324, 79\u201389 (2020).","journal-title":"JAMA"},{"key":"15_CR8","doi-asserted-by":"publisher","first-page":"1100","DOI":"10.1016\/j.cardfail.2024.02.014","volume":"30","author":"N Chan","year":"2024","unstructured":"Chan, N. et al. Temporal outcomes of patients diagnosed with transthyretin cardiac amyloidosis. J. Card. Fail 30, 1100\u20131107 (2024).","journal-title":"J. Card. Fail"},{"key":"15_CR9","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1097\/HCO.0000000000001156","volume":"39","author":"D Bampatsias","year":"2024","unstructured":"Bampatsias, D., Wardhere, A. & Maurer, M. S. Treatment of transthyretin cardiac amyloidosis. Curr. Opin. Cardiol. 39, 407\u2013416 (2024).","journal-title":"Curr. Opin. Cardiol."},{"key":"15_CR10","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1002\/ajh.27177","volume":"99","author":"MA Gertz","year":"2024","unstructured":"Gertz, M. A. Immunoglobulin light chain amyloidosis: 2024 update on diagnosis, prognosis, and treatment. Am. J. Hematol. 99, 309\u2013324 (2024).","journal-title":"Am. J. Hematol."},{"key":"15_CR11","first-page":"53","volume":"14","author":"BT Fitzgerald","year":"2017","unstructured":"Fitzgerald, B. T., Bashford, J., Newbigin, K. & Scalia, G. M. Regression of cardiac amyloidosis following stem cell transplantation: a comparison between echocardiography and cardiac magnetic resonance imaging in long-term survivors. Int J. Cardiol. Heart Vasc. 14, 53\u201357 (2017).","journal-title":"Int J. Cardiol. Heart Vasc."},{"key":"15_CR12","doi-asserted-by":"publisher","first-page":"1038","DOI":"10.1016\/j.jcmg.2023.02.019","volume":"16","author":"A Ioannou","year":"2023","unstructured":"Ioannou, A. et al. Tracking multiorgan treatment response in systemic al-amyloidosis with cardiac magnetic resonance derived extracellular volume mapping. JACC Cardiovasc Imaging 16, 1038\u20131052 (2023).","journal-title":"JACC Cardiovasc Imaging"},{"key":"15_CR13","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/j.jcmg.2020.07.043","volume":"14","author":"M Fontana","year":"2021","unstructured":"Fontana, M. et al. Reduction in CMR derived extracellular volume with Patisiran indicates cardiac amyloid regression. JACC Cardiovasc Imaging 14, 189\u2013199 (2021).","journal-title":"JACC Cardiovasc Imaging"},{"key":"15_CR14","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1080\/13506129.2021.1920389","volume":"28","author":"RK Patel","year":"2021","unstructured":"Patel, R. K., Fontana, M., Hawkins, P. N. & Gillmore, J. Splenic regression of amyloid on multi-modality imaging in response to treatment with patisiran and diflunisal in hereditary transthyretin amyloidosis. Amyloid 28, 269\u2013270 (2021).","journal-title":"Amyloid"},{"key":"15_CR15","doi-asserted-by":"publisher","first-page":"2199","DOI":"10.1056\/NEJMc2304584","volume":"388","author":"M Fontana","year":"2023","unstructured":"Fontana, M. et al. Antibody-associated reversal of ATTR Amyloidosis-related Cardiomyopathy. N. Engl. J. Med 388, 2199\u20132201 (2023).","journal-title":"N. Engl. J. Med"},{"key":"15_CR16","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1007\/s40259-022-00550-w","volume":"36","author":"M Nuvolone","year":"2022","unstructured":"Nuvolone, M., Nevone, A. & Merlini, G. Targeting Amyloid fibrils by passive immunotherapy in systemic amyloidosis. BioDrugs 36, 591\u2013608 (2022).","journal-title":"BioDrugs"},{"key":"15_CR17","doi-asserted-by":"crossref","unstructured":"Chakrabartty, A. Structural basis for monoclonal antibody therapy for transthyretin amyloidosis. Pharmaceuticals 17, 1225 (2024).","DOI":"10.3390\/ph17091225"},{"key":"15_CR18","doi-asserted-by":"publisher","first-page":"1068","DOI":"10.1080\/10428194.2024.2337803","volume":"65","author":"G Palladini","year":"2024","unstructured":"Palladini, G. et al. The mechanism of action, pharmacological characteristics, and clinical utility of the amyloid depleter birtamimab for the potential treatment of AL amyloidosis. Leuk. Lymphoma 65, 1068\u20131078 (2024).","journal-title":"Leuk. Lymphoma"},{"key":"15_CR19","doi-asserted-by":"publisher","first-page":"13049","DOI":"10.1021\/bi701255m","volume":"46","author":"B O\u2019Nuallain","year":"2007","unstructured":"O\u2019Nuallain, B. et al. Phage display and peptide mapping of an immunoglobulin light chain fibril-related conformational epitope. Biochemistry 46, 13049\u201313058 (2007).","journal-title":"Biochemistry"},{"key":"15_CR20","doi-asserted-by":"publisher","first-page":"1240","DOI":"10.1021\/bi0616605","volume":"46","author":"B O\u2019Nuallain","year":"2007","unstructured":"O\u2019Nuallain, B. et al. Localization of a conformational epitope common to non-native and fibrillar immunoglobulin light chains. Biochemistry 46, 1240\u20131247 (2007).","journal-title":"Biochemistry"},{"key":"15_CR21","doi-asserted-by":"publisher","first-page":"7657","DOI":"10.3390\/molecules20057657","volume":"20","author":"JS Wall","year":"2015","unstructured":"Wall, J. S. et al. Preclinical validation of the Heparin-reactive peptide p5+14 as a molecular imaging agent for visceral amyloidosis. Molecules 20, 7657\u20137682 (2015).","journal-title":"Molecules"},{"key":"15_CR22","doi-asserted-by":"publisher","first-page":"1419","DOI":"10.1016\/j.jcmg.2023.07.007","volume":"16","author":"OF Clerc","year":"2023","unstructured":"Clerc, O. F. et al. Cardiac Amyloid Quantification Using (124)I-Evuzamitide ((124)I-P5+14) Versus (18)F-Florbetapir: A Pilot PET\/CT Study. JACC Cardiovasc. Imaging 16, 1419\u20131432 (2023).","journal-title":"JACC Cardiovasc. Imaging"},{"key":"15_CR23","doi-asserted-by":"publisher","first-page":"1433","DOI":"10.1016\/j.jcmg.2023.08.009","volume":"16","author":"JS Wall","year":"2023","unstructured":"Wall, J. S. et al. Cardiac Amyloid Detection by PET\/CT Imaging of Iodine ((124)I) Evuzamitide ((124)I-p5+14): A Phase 1\/2 Study. JACC Cardiovasc. Imaging 16, 1433\u20131448 (2023).","journal-title":"JACC Cardiovasc. Imaging"},{"key":"15_CR24","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/j.bbrc.2013.05.063","volume":"436","author":"EB Martin","year":"2013","unstructured":"Martin, E. B. et al. Peptide p5 binds both heparinase-sensitive glycosaminoglycans and fibrils in patient-derived AL amyloid extracts. Biochem. Biophys. Res. Commun. 436, 85\u201389 (2013).","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"15_CR25","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1007\/s11307-011-0524-0","volume":"14","author":"JS Wall","year":"2012","unstructured":"Wall, J. S. et al. Comparative analysis of peptide p5 and serum amyloid P component for imaging AA amyloid in mice using dual-isotope SPECT. Mol. Imaging Biol. 14, 402\u2013407 (2012).","journal-title":"Mol. Imaging Biol."},{"key":"15_CR26","doi-asserted-by":"publisher","first-page":"e66181","DOI":"10.1371\/journal.pone.0066181","volume":"8","author":"JS Wall","year":"2013","unstructured":"Wall, J. S. et al. A binding-site barrier affects imaging efficiency of high affinity amyloid-reactive peptide radiotracers in vivo. PLoS One 8, e66181 (2013).","journal-title":"PLoS One"},{"key":"15_CR27","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1016\/j.jmb.2010.10.059","volume":"405","author":"C Haupt","year":"2011","unstructured":"Haupt, C. et al. Amyloid fibril recognition with the conformational B10 antibody fragment depends on electrostatic interactions. J. Mol. Biol. 405, 341\u2013348 (2011).","journal-title":"J. Mol. Biol."},{"key":"15_CR28","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1275372","volume":"14","author":"JS Foster","year":"2023","unstructured":"Foster, J. S. et al. Development and characterization of a prototypic pan-amyloid clearing agent - a novel murine peptide-immunoglobulin fusion. Front. Immunol. 14, 1275372 (2023).","journal-title":"Front. Immunol."},{"key":"15_CR29","doi-asserted-by":"publisher","first-page":"1082","DOI":"10.3389\/fimmu.2017.01082","volume":"8","author":"JS Foster","year":"2017","unstructured":"Foster, J. S. et al. A Peptide-Fc Opsonin with pan-amyloid reactivity. Front Immunol. 8, 1082 (2017).","journal-title":"Front Immunol."},{"key":"15_CR30","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1007\/s10719-018-9833-8","volume":"35","author":"K Nishitsuji","year":"2018","unstructured":"Nishitsuji, K. Heparan sulfate S-domains and extracellular sulfatases (Sulfs): their possible roles in protein aggregation diseases. Glycoconj. J. 35, 387\u2013396 (2018).","journal-title":"Glycoconj. J."},{"key":"15_CR31","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1016\/S0006-3495(98)77529-0","volume":"75","author":"CN Pace","year":"1998","unstructured":"Pace, C. N. & Scholtz, J. M. A helix propensity scale based on experimental studies of peptides and proteins. Biophys. J. 75, 422\u2013427 (1998).","journal-title":"Biophys. J."},{"key":"15_CR32","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1002\/bip.21339","volume":"93","author":"A Rullo","year":"2010","unstructured":"Rullo, A. & Nitz, M. Importance of the spatial display of charged residues in heparin-peptide interactions. Biopolymers 93, 290\u2013298 (2010).","journal-title":"Biopolymers"},{"key":"15_CR33","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1006\/abbi.1995.9963","volume":"323","author":"JR Fromm","year":"1995","unstructured":"Fromm, J. R., Hileman, R. E., Caldwell, E. E., Weiler, J. M. & Linhardt, R. J. Differences in the interaction of heparin with arginine and lysine and the importance of these basic amino acids in the binding of heparin to acidic fibroblast growth factor. Arch. Biochem. Biophys. 323, 279\u2013287 (1995).","journal-title":"Arch. Biochem. Biophys."},{"key":"15_CR34","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1080\/13506120601116419","volume":"14","author":"R Kisilevsky","year":"2007","unstructured":"Kisilevsky, R., Ancsin, J. B., Szarek, W. A. & Petanceska, S. Heparan sulfate as a therapeutic target in amyloidogenesis: prospects and possible complications. Amyloid 14, 21\u201332 (2007).","journal-title":"Amyloid"},{"key":"15_CR35","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1160\/TH07-04-0310","volume":"98","author":"U Lindahl","year":"2007","unstructured":"Lindahl, U. Heparan sulfate-protein interactions-a concept for drug design? Thromb. Haemost. 98, 109\u2013115 (2007).","journal-title":"Thromb. Haemost."},{"key":"15_CR36","doi-asserted-by":"publisher","first-page":"6473","DOI":"10.1073\/pnas.0502287102","volume":"102","author":"JP Li","year":"2005","unstructured":"Li, J. P. et al. In vivo fragmentation of heparan sulfate by heparanase overexpression renders mice resistant to amyloid protein A amyloidosis. Proc. Natl Acad. Sci. USA 102, 6473\u20136477 (2005).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"15_CR37","doi-asserted-by":"publisher","first-page":"67","DOI":"10.3109\/13506129.2016.1168292","volume":"23","author":"H Takase","year":"2016","unstructured":"Takase, H. et al. Structural requirements of glycosaminoglycans for facilitating amyloid fibril formation of human serum amyloid A. Amyloid 23, 67\u201375 (2016).","journal-title":"Amyloid"},{"key":"15_CR38","doi-asserted-by":"publisher","first-page":"26091","DOI":"10.1074\/jbc.272.42.26091","volume":"272","author":"B Lindahl","year":"1997","unstructured":"Lindahl, B. & Lindahl, U. Amyloid-specific heparan sulfate from human liver and spleen. J. Biol. Chem. 272, 26091\u201326094 (1997).","journal-title":"J. Biol. Chem."},{"key":"15_CR39","doi-asserted-by":"publisher","first-page":"e1011487","DOI":"10.1371\/journal.ppat.1011487","volume":"19","author":"P Aguilar-Calvo","year":"2023","unstructured":"Aguilar-Calvo, P. et al. Neuronal Ndst1 depletion accelerates prion protein clearance and slows neurodegeneration in prion infection. PLoS Pathog. 19, e1011487 (2023).","journal-title":"PLoS Pathog."},{"key":"15_CR40","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1080\/13506129.2022.2155133","volume":"30","author":"JW Jackson","year":"2023","unstructured":"Jackson, J. W. et al. Collagen inhibits phagocytosis of amyloid in vitro and in vivo and may act as a \u2018don\u2019t eat me\u2019 signal. Amyloid 30, 249\u2013260 (2023).","journal-title":"Amyloid"},{"key":"15_CR41","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1042\/cs0870289","volume":"87","author":"PN Hawkins","year":"1994","unstructured":"Hawkins, P. N. Studies with radiolabelled serum amyloid P component provide evidence for turnover and regression of amyloid deposits in vivo. Clin. Sci. 87, 289\u2013295 (1994).","journal-title":"Clin. Sci."},{"key":"15_CR42","doi-asserted-by":"publisher","first-page":"1094","DOI":"10.3324\/haematol.2008.004119","volume":"94","author":"G van II","year":"2009","unstructured":"van, G. II, van Rijswijk, M. H., Bijzet, J., Vellenga, E. & Hazenberg, B. P. Histological regression of amyloid in AL amyloidosis is exclusively seen after normalization of serum free light chain. Haematologica 94, 1094\u20131100 (2009).","journal-title":"Haematologica"},{"key":"15_CR43","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1016\/j.jcmg.2017.02.012","volume":"11","author":"A Martinez-Naharro","year":"2018","unstructured":"Martinez-Naharro, A. et al. CMR-verified regression of cardiac AL amyloid after chemotherapy. JACC Cardiovasc Imaging 11, 152\u2013154 (2018).","journal-title":"JACC Cardiovasc Imaging"},{"key":"15_CR44","doi-asserted-by":"publisher","first-page":"138","DOI":"10.3109\/13506129.2012.711391","volume":"19","author":"SN Nystrom","year":"2012","unstructured":"Nystrom, S. N. & Westermark, G. T. AA-Amyloid is cleared by endogenous immunological mechanisms. Amyloid 19, 138\u2013145 (2012).","journal-title":"Amyloid"},{"key":"15_CR45","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1038\/22124","volume":"400","author":"D Schenk","year":"1999","unstructured":"Schenk, D. et al. Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature 400, 173\u2013177 (1999).","journal-title":"Nature"},{"key":"15_CR46","doi-asserted-by":"publisher","first-page":"1239","DOI":"10.1016\/S0002-9440(10)64639-1","volume":"157","author":"R Hrncic","year":"2000","unstructured":"Hrncic, R. et al. Antibody-mediated resolution of light chain-associated amyloid deposits. Am. J. Pathol. 157, 1239\u20131246 (2000).","journal-title":"Am. J. Pathol."},{"key":"15_CR47","doi-asserted-by":"publisher","first-page":"1768","DOI":"10.1212\/WNL.0000000000003904","volume":"88","author":"NR Relkin","year":"2017","unstructured":"Relkin, N. R. et al. A phase 3 trial of IV immunoglobulin for Alzheimer disease. Neurology 88, 1768\u20131775 (2017).","journal-title":"Neurology"},{"key":"15_CR48","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-23274-x","volume":"12","author":"A Michalon","year":"2021","unstructured":"Michalon, A. et al. A human antibody selective for transthyretin amyloid removes cardiac amyloid through phagocytic immune cells. Nat. Commun. 12, 3142 (2021).","journal-title":"Nat. Commun."},{"key":"15_CR49","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1056\/NEJMoa2303765","volume":"389","author":"P Garcia-Pavia","year":"2023","unstructured":"Garcia-Pavia, P. et al. Phase 1 trial of Antibody NI006 for depletion of cardiac transthyretin amyloid. N. Engl. J. Med 389, 239\u2013250 (2023).","journal-title":"N. Engl. J. Med"},{"key":"15_CR50","doi-asserted-by":"crossref","unstructured":"Suhr, O. B. et al. PRX004 in variant amyloid transthyretin (ATTRv) amyloidosis: results of a phase 1, open-label, dose-escalation study. Amyloid 32, 14\u201321 (2025).","DOI":"10.1080\/13506129.2024.2420809"},{"key":"15_CR51","doi-asserted-by":"publisher","first-page":"32","DOI":"10.3389\/fimmu.2011.00032","volume":"2","author":"JS Wall","year":"2011","unstructured":"Wall, J. S. et al. Generation and characterization of anti-AA amyloid-specific monoclonal antibodies. Front Immunol. 2, 32 (2011).","journal-title":"Front Immunol."},{"key":"15_CR52","doi-asserted-by":"publisher","first-page":"e52686","DOI":"10.1371\/journal.pone.0052686","volume":"7","author":"JS Wall","year":"2012","unstructured":"Wall, J. S. et al. AL amyloid imaging and therapy with a monoclonal antibody to a cryptic epitope on amyloid fibrils. PLoS One 7, e52686 (2012).","journal-title":"PLoS One"},{"key":"15_CR53","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1080\/13506129.2016.1205974","volume":"23","author":"M Renz","year":"2016","unstructured":"Renz, M. et al. 2A4 binds soluble and insoluble light chain aggregates from AL amyloidosis patients and promotes clearance of amyloid deposits by phagocytosis (dagger). Amyloid 23, 168\u2013177 (2016).","journal-title":"Amyloid"},{"key":"15_CR54","doi-asserted-by":"publisher","first-page":"1208","DOI":"10.1182\/blood.2022019406","volume":"142","author":"MA Gertz","year":"2023","unstructured":"Gertz, M. A. et al. Birtamimab plus standard of care in light-chain amyloidosis: the phase 3 randomized placebo-controlled VITAL trial. Blood 142, 1208\u20131218 (2023).","journal-title":"Blood"},{"key":"15_CR55","doi-asserted-by":"publisher","first-page":"2241","DOI":"10.1182\/blood-2010-03-273797","volume":"116","author":"JS Wall","year":"2010","unstructured":"Wall, J. S. et al. Radioimmunodetection of amyloid deposits in patients with AL amyloidosis. Blood 116, 2241\u20132244 (2010).","journal-title":"Blood"},{"key":"15_CR56","doi-asserted-by":"publisher","first-page":"e0301756","DOI":"10.1371\/journal.pone.0301756","volume":"19","author":"SJ Kennel","year":"2024","unstructured":"Kennel, S. J. et al. Preclinical evaluation of Tc-99m p5+14 peptide for SPECT detection of cardiac amyloidosis. PLoS One 19, e0301756 (2024).","journal-title":"PLoS One"},{"key":"15_CR57","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1080\/13506129.2017.1295372","volume":"24","author":"JS Wall","year":"2017","unstructured":"Wall, J. S. et al. A bifunctional peptide, \u201cpeptope\u201d, for pre-targeting antibody 7D8 to systemic amyloid deposits. Amyloid 24, 22\u201323 (2017).","journal-title":"Amyloid"},{"key":"15_CR58","doi-asserted-by":"publisher","first-page":"E10839","DOI":"10.1073\/pnas.1805515115","volume":"115","author":"JS Wall","year":"2018","unstructured":"Wall, J. S. et al. Bifunctional amyloid-reactive peptide promotes binding of antibody 11-1F4 to diverse amyloid types and enhances therapeutic efficacy. Proc. Natl Acad. Sci. USA 115, E10839\u2013E10848 (2018).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"15_CR59","first-page":"3831S","volume":"9","author":"A Solomon","year":"2003","unstructured":"Solomon, A., Weiss, D. T. & Wall, J. S. Therapeutic potential of chimeric amyloid-reactive monoclonal antibody 11-1F4. Clin. Cancer Res 9, 3831S\u20133838S (2003).","journal-title":"Clin. Cancer Res"},{"key":"15_CR60","doi-asserted-by":"publisher","first-page":"14101","DOI":"10.1021\/bi991131j","volume":"38","author":"J Wall","year":"1999","unstructured":"Wall, J. et al. Thermodynamic instability of human lambda 6 light chains: correlation with fibrillogenicity. Biochemistry 38, 14101\u201314108 (1999).","journal-title":"Biochemistry"},{"key":"15_CR61","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1172\/JCI105784","volume":"47","author":"M Pras","year":"1968","unstructured":"Pras, M., Schubert, M., Zucker-Franklin, D., Rimon, A. & Franklin, E. C. The characterization of soluble amyloid prepared in water. J. Clin. Invest. 47, 924\u2013933 (1968).","journal-title":"J. Clin. Invest."},{"key":"15_CR62","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/S0076-6879(85)16008-8","volume":"116","author":"A Solomon","year":"1985","unstructured":"Solomon, A. Light chains of human immunoglobulins. Methods Enzymol. 116, 101\u2013121 (1985).","journal-title":"Methods Enzymol."},{"key":"15_CR63","doi-asserted-by":"publisher","first-page":"3091","DOI":"10.4049\/jimmunol.146.9.3091","volume":"146","author":"M Eulitz","year":"1991","unstructured":"Eulitz, M., Murphy, C., Weiss, D. T. & Solomon, A. Serologic and chemical differentiation of human lambda III light chain variable regions. J. Immunol. 146, 3091\u20133096 (1991).","journal-title":"J. Immunol."},{"key":"15_CR64","doi-asserted-by":"publisher","first-page":"8276","DOI":"10.1021\/bi101280t","volume":"49","author":"J Du","year":"2010","unstructured":"Du, J. & Murphy, R. M. Characterization of the interaction of beta-amyloid with transthyretin monomers and tetramers. Biochemistry 49, 8276\u20138289 (2010).","journal-title":"Biochemistry"},{"key":"15_CR65","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1016\/j.jmb.2013.01.008","volume":"425","author":"KH Lim","year":"2013","unstructured":"Lim, K. H., Dyson, H. J., Kelly, J. W. & Wright, P. E. Localized structural fluctuations promote amyloidogenic conformations in transthyretin. J. Mol. Biol. 425, 977\u2013988 (2013).","journal-title":"J. Mol. Biol."},{"key":"15_CR66","first-page":"79","volume":"33","author":"G Stokes","year":"1976","unstructured":"Stokes, G. An improved Congo red method for amyloid. Med. Lab. Sci. 33, 79\u201380 (1976).","journal-title":"Med. Lab. Sci."},{"key":"15_CR67","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1080\/13506120500222359","volume":"12","author":"JS Wall","year":"2005","unstructured":"Wall, J. S. et al. Quantitative high-resolution microradiographic imaging of amyloid deposits in a novel murine model of AA amyloidosis. Amyloid 12, 149\u2013156 (2005).","journal-title":"Amyloid"},{"key":"15_CR68","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1016\/j.ajpath.2019.01.011","volume":"189","author":"T Richey","year":"2019","unstructured":"Richey, T. et al. Macrophage-mediated phagocytosis and dissolution of amyloid-like fibrils in mice, monitored by optical imaging. Am. J. Pathol. 189, 989\u2013998 (2019).","journal-title":"Am. J. Pathol."}],"container-title":["npj Drug Discovery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s44386-025-00015-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s44386-025-00015-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s44386-025-00015-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,8]],"date-time":"2025-09-08T13:29:54Z","timestamp":1757338194000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s44386-025-00015-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,4]]},"references-count":68,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["15"],"URL":"https:\/\/doi.org\/10.1038\/s44386-025-00015-4","relation":{},"ISSN":["3005-1452"],"issn-type":[{"value":"3005-1452","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,4]]},"assertion":[{"value":"18 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 May 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 August 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"TR, AS, EM, and SK are founding shareholders of Attralus, Inc. JW is a founding shareholder and interim CSO of Attralus, Inc. SG is a founding shareholder and COO of Attralus, Inc. JW, SK, AW, TH, S,G and JF have rights in intellectual property related to antibody-peptide fusion proteins. SG, MK, and NA are employees and shareholders of Attralus, Inc.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"18"}}